Skip to main content

Table 1 Characteristics of the global cohort and patients having 2 measurements of mHLA-DR

From: Monitoring of circulating monocyte HLA-DR expression in a large cohort of intensive care patients: relation with secondary infections

Parameters, n (%) or median [IQR] All patients (n = 1053) Patients with two mHLA-DR measurement (n = 592)
Age 59.3 [44.8; 71.8] 59.8 [46.5; 71.4]
Sex (female) 444 (42.2) 236 (39.9)
Comorbid condition
 Hypertension 399 (37.9) 197 (39.6)
 Cardiac insufficiency 233 (22.1) 100 (20.1)
 Immunosuppression 229 (21.7) 94 (18.9)
 Diabetes 155 (14.7) 81 (16.3)
 Respiratory failure 98 (9.3) 46 (9.3)
 Chronic kidney disease 91 (8.6) 39 (7.8)
 Cirrhosis 47 (4.5) 17 (3.4)
Diagnostic on admission
Sepsis 255 (24.2) 170 (28.7)
 Septic shock (classic definition) 77 (7.3) 72 (42.4)
Origin of the infection
 Cutaneous 83 (32.5) 61 (35.9)
 Respiratory 65 (25.5) 46 (27.1)
 Abdominal 61 (23.9) 36 (21.2)
 Neurologic 15 (5.9 11 (6.5)
 Urinary 18 (7.1) 9 (5.3)
 Others 13 (5.1) 7 (4.1)
Neurologic admission 384 (36.5) 248 (41.9)
 Subarachnoid hemorrhage 103 (26.8) 75 (30.2)
 Brain Traumatism 68 (17.7) 49 (19.8)
 Intra cranial hemorrhage 68 (17.7) 42 (16.9)
 Neurological surgery 63 (16.4) 32 (12.9)
 Ischemic stroke 50 (13) 27 (10.9)
 Subdural hematoma 18 (4.7) 10 (4)
 Others 17 (4.4) 13 (5.2)
Post-surgical care 80 (7.6) 41 (6.9)
 Abdominal 59 (73.8) 33 (80.5)
 ORL 8 (10) 5 (12.2)
 Orthopedics 8 (10) 2 (4.9)
 Others 5 (6.3) 1 (2.4)
Miscellaneous 334 (31.7) 133 (22.5)
 Hemorrhagic shock 67 (20.1) 30 (22.6)
 Respiratory failure from a medical origin 79 (23.7) 27 (20.3)
 Polytrauma 37 (11.1) 25 (18.8)
 Medical abdominal disease 31 (9.3) 13 (9.8)
 Obstetrical 24 (7.2) 6 (4.5)
 Cardiac arrest 13 (3.9) 5 (3.8)
 Others 83 (24.9) 27 (20.3)
Severity on admission   
 Day 1 SAPS II (miss = 6) 37 [25; 50] 39 [28; 51]
 Day 1 SOFA (neuro excluded) (miss = 6) 4 [2; 7] 5 [2; 8]
HLA-DR Cell count measurements
 Delay from admission to mHLA-DR measurement, days (1st/2nd) 2 [1; 3] 2 [1; 3]/5 [4; 7]
 Log mHLA-DR (1st/2nd) 9.2 [8.7; 9.7] 9.1 [8.7; 9.6]/9.2 [8.7; 9.6]
 Low mHLA-DR, <  000 AB/C (1st/2nd) 403 (38.3) 253 (42.7)/221 (37.3)
 Leucocytes, 109/L (1st/2nd) 10.8 [8.5; 14.4] 11.1 [8.9; 15.1]/11 [8.6; 4.5]
 Neutrophils, 109/L (1st/2nd) 8.5 [6.4; 11.8] 9 [6.6; 12.5]/8.6 [6.2; 11.7]
 Lymphocytes, 109/L (1st/2nd) 1.3 [0.9; 1.7] 1.2 [0.8; 1.7]/1.3 [1; 1.8]
 Monocytes, 109/L (1st/2nd) 0.7 [0.5; 1] 0.8 [0.5; 1.1]/0.8 [0.6; 1.1]
Outcomes
 Delay before 1st ICU-acquired infection (days) 7 [5; 10.5] 7 [5; 11]
 Number of ICU-acquired infections 245 (23.3) 223 (37.7)
 Source of ICU-acquired infection   
  Respiratory 138 (13.1) 126 (21.3)
  Abdominal 44 (4.2) 40 (6.8)
  Bacteremia, catheter-related 40 (3.8) 35 (5.9)
  Others 23 (2.2) 22 (3.7)
 ICU length of stay 7 [4; 14] 13 [8; 22]
 Delay before death 6 [3; 14] 13 [8; 25]
 ICU death 151 (14.3) 79 (13.3)
 Early death, (< day 7, n = 1040) 82 (7.9)
 Late ICU death (among patients alive at day 7, n = 499)   60 (12)
  1. IQR: interquartile; ICU: Intensive Care Unit; SAPS: Simplified Acute Physiology Score; SOFA: Sequential Organ Failure Assessment; NLCR: neutrophil-to-lymphocyte count ratio; mHLA-DR: monocytic human leukocyte antigen-antigen D related; AB/C: antibody per cell. For diagnostic at admission, data are expressed as percentage within the subgroups